Incyte Corp - ESG Rating & Company Profile powered by AI
This article contains a questions and answers table for Incyte Corp. This report of Incyte Corp is prepared by All Street Sevva using advanced Cognitive Robots. Full ESG assessment of Incyte Corp can be reached by signing in.
Incyte Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 4.0, social score of 5.0 and governance score of 2.3.
3.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1089 | Zymeworks Inc | 3.9 | Medium |
| 1089 | bluebird bio Inc | 3.9 | Medium |
| 1112 | Incyte Corp | 3.8 | Medium |
| 1112 | AcelRx Pharmaceuticals Inc | 3.8 | Medium |
| 1112 | Arcus Biosciences Inc | 3.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Incyte Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Incyte Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes Incyte Corp report the average age of the workforce?
Sign up for free to unlockDoes Incyte Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Incyte Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes Incyte Corp disclose cybersecurity risks?
Sign up for free to unlockDoes Incyte Corp offer flexible work?
Sign up for free to unlockDoes Incyte Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Incyte Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Incyte Corp conduct supply chain audits?
Sign up for free to unlockDoes Incyte Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Incyte Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes Incyte Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes Incyte Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Incyte Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Incyte Corp disclose water use targets?
Sign up for free to unlockDoes Incyte Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid Incyte Corp have a product recall in the last two years?
Sign up for free to unlockDoes Incyte Corp disclose incidents of discrimination?
Sign up for free to unlockDoes Incyte Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Incyte Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Incyte Corp disclose parental leave metrics?
Sign up for free to unlockDoes Incyte Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Incyte Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Incyte Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes Incyte Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Incyte Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Incyte Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Incyte Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes Incyte Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Incyte Corp disclose its waste policy?
Sign up for free to unlockDoes Incyte Corp report according to TCFD requirements?
Sign up for free to unlockDoes Incyte Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Incyte Corp disclose energy use targets?
Sign up for free to unlockDoes Incyte Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Incyte Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Incyte Corp
These potential risks are based on the size, segment and geographies of the company.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.